CN Patent

CN121843712A — 用于治疗多发性硬化症的组合物和方法

Assigned to F Hoffmann La Roche AG · Expires 2026-04-10 · 0y expired

What this patent protects

本发明涉及用于治疗患者的多发性硬化症(MS)的方法，在一些情况下，所述方法涉及以约920 mg的剂量将抗CD20抗体皮下施用到患者中。还包括组合物、制剂和带有针对此类用途的说明书的制品。

USPTO Abstract

本发明涉及用于治疗患者的多发性硬化症(MS)的方法，在一些情况下，所述方法涉及以约920 mg的剂量将抗CD20抗体皮下施用到患者中。还包括组合物、制剂和带有针对此类用途的说明书的制品。

Drugs covered by this patent

Patent Metadata

Patent number
CN121843712A
Jurisdiction
CN
Classification
—
Expires
2026-04-10
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.